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Oral cancer is one of the major global threats to public health. Oral cancer development is a tobacco-related multistep and
multifocalprocess involving ﬁeld cancerizationand carcinogenesis.The rationaleformolecular-targeted prevention oforalcancer
is promising.Biomarkers of genomic instability, including aneuploidy and allelic imbalance, are able to measure the cancer risk of
oral premalignancies. Understanding of the biology of oral carcinogenesis will give us important advances for detecting high-risk
patients, monitoring preventive interventions, assessing cancer risk, and pharmacogenomics.In addition, novel chemopreventive
agents based on molecular mechanisms and targets against oral cancers will be derived from research using appropriate animal
carcinogenesismodels.Newapproaches, suchasinterventionswithmolecular-targeted agentsandagentcombinationsinhigh-risk
oral individuals, are undoubtedly needed to reduce the devastating worldwide consequences of oral malignancy.
1.Introduction
Head and neck cancer is the sixth most common human
cancer [1], representing 3% of all types of cancer. They are
located in the oral cavity in 48% of cases, and 90% of these
are oral squamous cell carcinoma [2]. They are sometimes
preceded by precancerous lesions, such as leukoplakia and
erythroplakia. More than 300,000 new cases worldwide are
beingdiagnosed with oral squamouscell carcinoma annually
[3].Approximately35,000newcasesarerecordedannuallyin
the US [2], 40,000 new cases in the EU, and 10915 new cases
in Japan [4]. The most common site for intraoral carcinoma
is the tongue, which accounts for around 40% of all cases in
the oral cavity proper. Tongue cancers most frequently occur
on the posteriorlateral border and ventral surfaces of the
tongue. The ﬂoor of the mouth is the second most common
intraoral location. Less common sites include the gingival,
buccal mucosa, labial mucosa, and hard plate.
The incidence of oral cancer has signiﬁcant local varia-
tion. In India and other Asian countries, oral and pharyngeal
carcinomas comprise up to half of all malignancies, with this
particularly high prevalencebeing attributedto the inﬂuence
of carcinogens and region-speciﬁc epidemiological factors,
especiallytobaccoandbetelquidchewing.Anincreaseinoral
cancer prevalence among young adults is a cause of special
concern. There has been a 60% increase in the number of
under 40 years old with tongue cancer over past 30 years.
However, few data have been published on the etiology
and natural history of this increase [5]. Oral malignancy
including tongue cancer is associated with severe morbidity
and less than 50% long-term survival despite advances in
treatment (surgery, radiation, and chemotherapy) of oral
cancer. The survival of the patients remains very low, mainly
due to their high risk of developing a second primary
cancer. Thus, early detection and prevention of oral cancer
and premalignancy are quite important [6–10]. This paper
will focus on our understanding of oral carcinogenesis for
preventing and early detection of oral malignancy.
2.Oral Carcinogenesis
Oral carcinogenesis is a highly complex multifocal process
that takes place when squamous epithelium is aﬀected by2 Journal of Oncology
several genetic alterations. The use of several molecular
biology techniques to diagnose oral precancerous lesions
and cancer may markedly improve the early detection of
alterations that are invisible under the microscope. This
would identify patients at a high risk of developing oral
cancer [11]. Natural history of oral cancer and sequence
of genetic alterations are illustrated in Figure 1.T h e r ea r e
approaches to understanding of the molecular basis of
oral cancer [12–14]. They include microarray technology,
methylation microarrays, gene expression microarrays, array
comparative genomic hybridization, proteomics, mitochon-
drial arrays, and micro-RNA arrays [15]. To date, high-
throughout approaches are being used to search for oral
cancer biomarkers in bioﬂuids (saliva and serum) [15].
“Field cancerization” refers to the potential development
of cancer at multiple sites [16, 17]. This has been observed
during the development of cancer in the tissues covered
with squamous epithelium (head and neck tumor) and
transitional epithelium (urothelial carcinoma). It is evident
that oral cancer, like carcinomas in other tissues, develops
over many years, and during this period, there are multiple
sites of neoplastic transformation occurring throughout the
oral cavity. Mutations of this gene have been observed in
various sites of premalignant leukoplakia and carcinoma in
the same oral cavity [18]. A reduction in tumor suppressor
activity by the gene and the development of mutations in
p53 have been associated with smoking and an increased
risk for oral carcinoma development [19]. Therefore, multi-
focal presentations and mutational expressions of tumor
suppressor genes may be the consequence of long-term
(e.g., 20∼40 years) exposure to various environmental and
exogenous factors. The continual presence of mutations may
also signify changes in DNA repair and apoptosis, thereby
increasingthesusceptibilityforfuturetransformation. Muta-
tional adaptations that modify the survivability of particular
clones of transforming cells may also further enhance the
level of resistance to therapeutic control. Recent genetic
analysis has revealed that cancers developing at distant sites
within the oral cavity often are derived from the same initial
clone[20].Themultiplicityoftheoralcarcinogenesisprocess
makes it diﬃcult to interrupt the progression to cancer
through surgical removal of a premalignant lesion.
3.RiskFactorsof OralCancer
The most important risk factor for the development of
oral cancer in the Western countries is the consumption
of tobacco [21]a n da l c o h o l[ 22]. Although drinking and
smoking are independent risk factors, they have a synergistic
eﬀect and greatly increase risk together. In Asian countries,
the use of smokeless tobacco products such as gutkha
and betel quid [5, 23] is responsible for a considerable
percentage of oral cancer cases. Several studies have reported
a signiﬁcant familial component in the development of oral
cancer. The estimates of risk in the ﬁrst degree relatives of
oral cancer patients vary widely and have been reported
to be 1.1 [24] ∼ 3.8 [25] although some of these refer to
head and neck cancer in general. Familial aggregation of
oral cancer, possibly with an autosomal dominant mode of
inheritance, was reported in a very small percentage of oral
cancer patients [26]. Polymorphic variation of genes in the
xenobiotic metabolism pathways, such as in CYP1A1 or the
genes coding for glutathione S-transferase-M1 [27, 28]a n d
N-acetyltransferase-2 [29] may be implicated. Individuals
that carry the fast-metabolizing alcohol dehydrogenase type
3( ADH3)a l l e l e[ 30] may be particularly vulnerable to the
eﬀects of chronic alcohol consumption and could be at
increased risk to develop oral cancer [31].
Human papilloma virus (HPV), particularly HPV type
16, may be an etiologic factor, especially among persons
who do not smoke or drink alcohol [32, 33]. Ang et al.
[34] reported that tumor HPV status is a strong and inde-
pendent prognostic factor for survival among patients with
oropharyngeal cancer. They also noted that the risk of death
signiﬁcantly increased with each additional pack year of
tobacco smoking. Although the idea that bacterial infections
could lead to oral cancer has not been well regarded, there
recently has been an increasing body of evidence to suggest
a possible relationship between microorganisms and oral
cancer development. The most notable example is that of
the common pathogenic bacterium Helicobacter pylori and
its association with gastric cancer. The mouth comprises a
variety of diﬀerent surfaces that are home to a huge diversity
of microorganisms, including more than 750 distinct taxa
of bacteria, suggesting that the oral squamous epithelium
is constantly exposed to a variety of microbial challenges,
on both cellular and molecular levels. In this context, we
should draw attention to how they may relate to oral cancer
development [35, 36].
There are clinically apparent oral premalignant lesions of
oral cancer. They include leukoplakia, erythroplakia, nico-
tine stomatitis and tobacco pouch keratosis, lichen planus,
and submucous ﬁbrosis [37]. The term “leukoplakia” ﬁrst
used by Schwimmer in 1877 [38] to describe a white lesion
of the tongue probably represented a syphilitic glossitis.
The deﬁnition of leukoplakia has often been confusing and
controversial. Some clinicians now avoid using this term.
As deﬁned by the World Health Organization, leukoplakia
is “a white patch or plaque that cannot be characterized
clinicallyorpathologicallyasanyotherdisease [39]”.Assuch,
leukoplakia should be used only as a clinical term. The term
has no speciﬁc histopathological connotation and should
never be used as a microscopic diagnosis. In the evaluation
of the patient, leukoplakia is a clinical diagnosis of exclusion.
Sometimes, a white patch is initially believed to represent
leukoplakia,butthebiopsyrevealsanotherspeciﬁcdiagnosis.
In such cases, the lesion should no longer be categorized as a
leukoplakia. Leukoplakia is seen most frequently in middle-
aged and older men, with an increasing prevalence with
age [40]. Fewer than 1% of men below the age of 30 have
leukoplakia, but the prevalence increases to an alarming 8%
in men over the age of 70 [40]. The prevalence in women
past the age of 70 is approximately 2%. The most common
sites are the buccal mucosa, alveolar mucosa, and lower lip.
However, lesions in the ﬂoor of mouth, lateral tongue, and
lower lip are most likely to show dysplastic or malignant
changes [41].Journal of Oncology 3
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Figure 1: Natural history and genetic alterations of oral carcinogenesis. (a), Normal oral mucosa, (b) papillary hyperplasia, (c) midl
dysplasia, (d) moderate dysplasia, (e) severe dysplasia, (f) carcinoma in situ, and (g) invasive squamous cell carcinoma (well diﬀerentiated).
The term “erythroplasia” originally used by Queyrat [42]
todescribeared,precancerouslesionofthepenisisusedfora
clinically and histopathologically similar process that occurs
on the oral mucosa. Similar to the deﬁnition for leukoplakia,
erythroplakia is a clinical term that refers to a red patch
that cannot be deﬁned clinically or pathologically as any
other condition [39]. This deﬁnition excludes inﬂammatory
conditions that may result in a red clinical appearance.
Oral erythroplakia occurs most frequently in older men
and appears as a red macule or plaque with a soft, velvety
texture. The ﬂoor of mouth, lateral tongue, retromolar pad,
and soft palate are the most common sites of involvement.
Often the lesion is well demarcated, but some examples may
gradually blend into the surrounding mucosa. Some lesions
may be intermixed with white areas (erythroleukoplakia).
Erythroplakia is often asymptomatic although some patients
may complain of a sore, burning sensation.
Nicotine stomatitis is a thickened, hyperkeratotic alter-
ation of the palatal mucosa that is most frequently related
to pipe smoking, but milder examples can also develop
secondarytocigar smokingor,rarely, from cigarette smoking
[39]. The palatal mucosa becomes thickened and hyperkera-
totic, sometimes developing a ﬁssured surface. The surface
often develops popular elevations with red centers, which
represent the inﬂamed openings of the minor salivary gland
ducts.
Detection and diagnosis of oral neoplasia has tradi-
tionally relied heavily on the clinical experience of the
examiners and their ability to recognize often subtle mor-
phologicchanges. However, some early malignant lesionsare
clinically indistinguishable from benign lesions, and some
patients develop carcinomas in the absence of clinically
identiﬁable oral premalignant lesions. Furthermore, it can
be diﬃcult even for experts to determine which oral
premalignant lesions are at signiﬁcant risk to progress to
invasive carcinoma. Therefore, an accurate, objective, and
noninvasive method to help identify premalignant lesions
and to distinguish those at risk of malignant conversion is
needed.
4.BiomarkersofOral Cancer
Biomarkers help in the evaluation of prevention or use of
therapies and the detection of the earliest stages of oral
mucosal malignant transformation. Biomarkers reveal the
genetic and molecular changes related to early, intermediate,
and late end points in the process of oral carcinogenesis
[43]. These biomarkers will reﬁne our ability to enhance the
prognosis, diagnosis, and treatment of oral carcinomas [44].
Genetic and molecular biomarkers will also determine the
eﬀectiveness and safety of chemopreventive agents. Chemo-
preventive agents are chemicals of natural or synthetic4 Journal of Oncology
origin. Unlike other drugs, which do not prevent disease,
chemopreventiveagentsreducetheincidenceofdiseasessuch
as cancer before clinical symptoms occur. This development
is critical for the understanding of early oral mucosal
transformation. Biomarkers will also reduce the number of
patients and the time for long-term follow up required to
deﬁne a signiﬁcant clinical response to a chemopreventive
agent [45, 46]. The markers may, therefore, clarify the types,
doses, frequencies, and regimens to achieve the maximum
level of beneﬁt from chemopreventiveagents. Decreasing the
cost of the clinical trials is another factor that drives the
development of biomarkers.
Biomarkers have been categorized following the recom-
mendation by the Committee on Biological Markers of the
National Research Council/National Academy of Sciences
[47]. They fall into broad groups that detect exposure, pro-
gression, susceptibility to carcinogens, and/or the responses
by the target cellular populations [46].
A distinct advantage to oral cancer studies is their
anatomical access to the developing premalignant and
malignant lesions. One could readily analyze biopsies of
the primary lesion as well as apparently normal mucosal
sites to determine the levels of DNA adducts and oral
cancer risk. DNA adduct studies and cytogenetic analyses
may also provide evidence for altered structure and func-
tion of susceptibility sites in the DNA following DNA-
b i n d i n gs t u d i e so fn u c l e a rp r o t e i n ss u c ha sp 5 3 .S o m e
researchers have focused on microscopic cytogenetic and
somatic mutation changes as early biologic markers. One
of the markers used to deﬁne chromosomal aberrations is
the staining for micronuclei in exfoliated buccal mucosal
cells [48]. Micronuclei have also been used to evaluate the
reversal of leukoplakia and the eﬀectiveness of retinoids,
carotenoids, and vitamin E [49, 50]. Other methods include
thedeterminationofaneuploidy,andtheassessment oflosses
and gains of genetic material particularly associated with
somatic and sex chromosomes. Other sites of chromosomal
aberrations are found in sister chromatid exchanges, and
allele typic variations designated by losses on chromosomes
3, 4, 5, 6, 8, 9, 11, 13, 17, and 19.
Some molecular biomarkers with potential diagnostic
relevance include DNA content and chromosome polysomy,
loss of heterozygosity, nucleolar organizer regions, histo-
blood group antigens, proliferation markers, increased
epidermal growth factor receptor (EGFR), and decreased
expression of retinoic acid receptor-β, p16, and p53 [51, 52].
Although a reliable, validated marker panel for providing
clinicallyuseful prognostic information in oral premalignant
lesions patients has not yet been established, the advent of
high throughputgenomicand proteomicanalysis techniques
may soon yield major advances toward a prognostically
relevant molecular classiﬁcation system (Table 1).
5.Animal ModelsforOralCarcinogenesis
A variety of animals has been used for the study of tumor
growth, the process of carcinogenesis and the preven-
tion/treatment research [8, 53–56]. The continual develop-
ment of transgenic or knockout mice has improved our
Table 1: Potential biomarkers for oral carcinogenesis.
Category Measures
Genomic biomarker
Micronuclei, DNA adduct, DNA content,
and chromosomalaberration
(polymorphism,alleic loss, gain, and
ampliﬁcation)
Oncogenic biomarker Oncogenic expression, modiﬁed tumor
suppressor genes, and Src genes
Proliferation
biomarker
Nuclear and cyclin-related antigens,
mitotic frequency, ornithine
decarboxylase (ODC), and polyamines
Diﬀerentiation
biomarker
Cytokeratins, transglutaminaseType I,
and transcription factor (AP)-1
Oxidative stress
biomarker
Glutathione S-transferase, stress proteins
(HSPs), and Superoxide dismutase
Apoptosis biomarker
Bcl-2 family, chromatin condensation
factors, caspases, and nucleosome
formation
Immunologic
biomarker Cytokines
understanding of the role of speciﬁc genes in tumor growth.
The most widely used animal models for oral carcinogenesis
are the hamster cheek pouch model [54, 57]a n dt h e4 -
nitroquinoline 1-oxide- (4-NQO-) induced oral (tongue)
carcinogenesis model [8, 53, 58, 59].
In the former model, a complete carcinogen, 7,12-
dimethylbenz(a)anthrac ene(DMB A,0.5%),isappliedt othe
hamster cheek pouch three times a week for 16 weeks. By
week 16, all animals exhibit invasive oral squamous cell
carcinoma. Many diﬀerent studieshave been conductedwith
the hamster buccal pouch model, and they have provided
an array of changes that are analogous to those observed
in human invasive oral carcinoma [54, 57]. These include
a mutation in codon 61 of Ha-ras,w h i c hm a n i f e s t e di n
an A→T transversion in the second position of codon 61,
resulting in an amino acid change from glycine to leucine.
Theexpression ofc-Ki-ras inmalignant tumorsofthepouch,
but not in the normal oral mucosa, has also been observed
at very early stages of tumor development [57]. Although
the hamster oral tumor model appears to parallel several
changes observed in human oral cancer, the hamster still has
several areas of uniqueness which must be considered in any
evaluations of results from oral carcinogenesis studies. The
hamster cheek pouch provides a relatively large surface area
of oral mucosa for the development of invasive carcinoma,
while the human does not possess this type of mucosal
structure. In contrast to humans, mice, or rats, the hamster
cheek pouch lacks lymphatic drainage, which allows various
drugs or molecules to accumulate in the pouch. The Syrian
hamster population was also derived from a small breeding
pair that resulted in a restricted polymorphism for the
antigen recognition region (Iaregion)and some ofthemajor
histocompatibility K and D regions [60]. In addition, the
number of T-cells in the hamster spleen exhibits a lower
number/gram weight of the organ as compared with the
mouse or human [60]. The hamster may also respond toJournal of Oncology 5
antigenic tumor sources with a natural killer macrophage
or granulocyte cytotoxicity rather than a T cell response
[60].
Thelatteranimalmodelsforthestudyoforalcarcinogen-
esis include those in rats and mice using the water-soluble
carcinogen, 4-NQO. The carcinogen is either supplied in
the water (20 ppm) for the rats [58, 61–74]o rb yp a i n t i n g
for the mice [75]. Administration with 4-NQO in drinking
water(20ppm)for 8weeks inrats and mice producestongue
lesions including squamous cell neoplasms (Figure 2)w i t h i n
32 weeks [71], while topical application of the carcinogen to
the mouse palates for up to 16 weeks, just like the hamster
model develops palate tumors within 49 weeks [75]. Since
the most common site for intraoral carcinoma is the tongue
and the drinking water administering of 4-NQO is a simple
andeasymethod,the4-NQO-inducedtonguecarcinogenesis
model is quite useful for investigating oral carcinogenesis
and identifying cancer chemopreventive agents [58, 61–
74, 76–84]. In the rat model, with the progression of oral
carcinogenesis, increased levels of polyamine synthesis have
been noted as well as nucleolar organizing regions (NORs)
[58].The mouse model with 4-NQO has demonstrated some
molecular mimicry of human oral cancers, as is true of
the hamster model [75]. A number of chemical carcinogens
including coal tar, 20-methylcholanthrene, DMBA, and 4-
NQO have been used in experimental oral carcinogenesis.
However, 4-NQO is the preferred carcinogen apart from
DMBA in the development of experimental oral carcinogen-
esis. 4-NQO is a water-soluble carcinogen, which induces
tumors predominantly in the oral cavity. It produces all the
stages of oral carcinogenesis and several lines of evidences
suggest that similar histological as well as molecular changes
are observed in the human system. There are several review
articles to collate the information available on mechanisms
of action of 4-NQO, and studies have been carried out for
the development of biomarkers and chemopreventive agents
using 4-NQO animal models [8–10, 53, 58, 59, 61–68, 70–
74].
The complexity and variety of biochemical changes
can increase tumor development is the p53−/− mice [85].
Unfortunately, this model and other genetic mouse models
havenotbeenexploitedforstudying therelationships among
chemical oral carcinogenesis, speciﬁc genetic defects, and
chemoprevention. Genetically altered mouse and rat mod-
els have been developed for evaluating molecular-targeted
prevention and treatment of oral carcinoma [56]. We have
developed rasH2 transgenic mouse carcinogenesis model
[86]a n dh u m a nc - H a - ras proto-oncogene transgenic rat
model [87] for chemoprevention studies on oral (tongue)
carcinogenesis.
6.Chemoprevention
Chemoprevention is the use of natural or synthetic sub-
stances to halt, delay, or reverse malignant progression in
tissuesatrisk todevelopinvasivecancer[8–10].Retinoidsare
the most extensively studied agents for chemoprevention of
oral cancer [88]. 13-cis-retinoic acid given for only 3 months
produced a clinical response rate of 67% versus 10% for
placebo. However, toxicities were considerable, and a very
high rate of relapse within 3 months of stopping treatment
was reported. Subsequent studies with retinoids in patients
with oral premalignant lesions have conﬁrmed clinical
and pathologic response rates though toxicities remain a
concern [89]. However, translational studies showed that
molecular abnormalities persisted in some patients with
completeclinicalandpathologicresponse toretinoidtherapy
[90], suggesting that cancer development may be delayed
rather than prevented by these agents. Other agents that
have been assessed in clinical trials for chemoprevention
activity in oral leukoplakia patients include vitamin E [44],
Bowman-Birk inhibitor concentrate (BBIC) derived from
soybeans [91], curcumin [92], and green tea polyphenol
epigallocatechin-3-gallate. Small clinical trials using oral
BBICrevealednosigniﬁcanttoxicityanda32%response rate
[91].
Attention is focused now on the development of agents
targeted to speciﬁc steps in the molecular progression
from normal to oral premalignancy to invasive carcinoma.
Examples of molecularly targeted agents that have shown
promise in vitro, in animal models, or in early clinical trials
include cyclooxygenase (COX)-2 inhibitors and epidermal
growth factor receptor EGFR inhibitors [93–95]. Data from
several sources suggest that the cyclooxygenase pathway is
a good target for oral cancer prevention. COX-2 is over-
expressed in head and neck squamous carcinoma [96],
and COX-2 inhibitors prevented oral cancer development
in animal models [97]. A randomized placebo-controlled
trial of the COX-2 inhibitor ketorolac administered as an
oral rinse in oral leukoplakia patients revealed that the
treatment was well tolerated but did not result in greater
clinical response than placebo [98]. However, analysis of the
results of this trial are confounded somewhat by the high
response rate (32%) in the placebo arm and diﬃculty in
determining whether topical delivery of the agent allowed
penetration to the damaged cells. The future of COX-
2 inhibitors as chemoprevention agents will also depend
on the determination of the extent of risk for cardiac
toxicities associated with this class of agents. The EGFR is
also a promising molecular target for intervention in oral
malignant progression [93–95]. EGFR is a receptor tyrosine
kinase that is overexpressed in oral dysplasia and invasive
cancer and associated with worse prognosis in patients
with head and neck squamous carcinoma [99, 100]. EGFR
inhibitors, alone or in combination with chemotherapy and
radiotherapy, have shown activity against head and neck
squamous carcinoma in clinical trials, and toxicities were
generally well tolerated [101]. Evidence has suggested that
combination therapy targeting COX-2 and EGFR may be
eﬃcacious [95, 102]. Although chemoprevention appears to
be a promising approach to managing oral premalignancy,
prospective clinical trials using speciﬁc agents, and strong
corollary translational and laboratory investigations, are
neededtoevaluateclinical,histologic,andmoleculareﬃcacy.
In the future, it may be possible and necessary to individual-
ize medicaltherapy tospeciﬁc geneticabnormalitiesdetected
within the oral mucosa.6 Journal of Oncology
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carcinoma.
7.Conclusion
Human oral cancer being the sixth largest group of malig-
nancies worldwide. Seventy percent of oral cancers appear
from premalignant lesions. The process of oral cancer for-
mation results from multiple sites of premalignant change in
theoralcavity(ﬁeldcancerization).Animal modelsare being
widely used, aiming for the development of diagnostic and
prognostic markers. The appearance of these premalignant
lesions is one distinct feature of human oral cancer. At
present, there is dearth of biomarkers to identify which of
theselesionswill turnintomalignancy. Regionallymphnode
metastasis and locoregional recurrence are the major factors
responsible for the limited survival of patients with oral
cancer. Paucity of early diagnostic and prognostic markers
is one of the contributory factors for higher mortality rates.
Determining high- and low-risk populations by measuring
reliable biomarkers help us to understand the dynamics and
prevention of oral cancer development. The quantitation
of genetic and molecular changes and the use of these
changes as markers for the detection and prevention of early
premalignant change require the harvesting of tissues and
cells. Promising technologies are being rapidly developed to
assistinlocalizationofabnormaloralmucosa,innoninvasive
and objective diagnosis and characterization of identiﬁed
mucosal lesions, and in therapy of patients with oral cancer.
Undoubtedly, the prevention or reduction in the smoking
of tobacco products and alcohol consumption would have
a profound inﬂuence on the incidence of oral cancer.
Chemoprevention also has an impact on the development of
malignant changes in the oral mucosa. Prevention through
chemopreventionand/orthe useof systemicmedications has
been an extensively studied strategy and continues to hold
promise as a way of diminishing the morbidityand mortality
associated with this malignancy.
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